Back to School: How biopharma can reboot drug development. Access exclusive analysis here
Schering-Plough (SGP) presented results of an open label Phase II dose-ranging study of PEG-Intron with its Rebetol ribavirin nucleoside analog in
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury